21-hydroxylase deficiency primary prevention

Congenital adrenal hyperplasia main page
21-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating 21-Hydroxylase Deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
21-hydroxylase deficiency primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 21-hydroxylase deficiency primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 21-hydroxylase deficiency primary prevention
CDC on 21-hydroxylase deficiency primary prevention
21-hydroxylase deficiency primary prevention in the news
Blogs on 21-hydroxylase deficiency primary prevention
Directions to Hospitals Treating 21-Hydroxylase Deficiency
Risk calculators and risk factors for 21-hydroxylase deficiency primary prevention

Overview

There are no primary preventive measures available for congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Primary prevention

There are no primary preventive measures available for congenital adrenal hyperplasia due to 21-hydroxylase deficiency.